Skip to main content
DWTX
NASDAQ Life Sciences

Dogwood Therapeutics Secures Potential $100M Partnership, Narrows Q1 Loss, Extends Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.85
Mkt Cap
$62.127M
52W Low
$1.28
52W High
$9.5
52W Position info
45% above low
Off High info
81% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

DWTX sits 45% above its 52-week low of $1.28 on elevated volume (1.8× avg).

Summary

Dogwood Therapeutics announced a potential $100 million partnership for its antiviral assets and reported a narrowed Q1 net loss, extending its cash runway.


Key Events · M&A and Partnerships · DWTX

  • New Partnership Announced

    Secured a worldwide development and commercialization partnership for legacy antiviral assets with a potential value of up to $100 million.

  • Q1 Net Loss Significantly Narrowed

    Reported a Q1 2026 net loss of $5.0 million, a substantial improvement from $12.2 million in Q1 2025.

  • Cash Runway Extended

    Cash on hand of $13.2 million provides an operational runway into the fourth quarter of 2026.

  • Pipeline Progress Continues

    Halneuron® Phase 2b trial is on track for top-line results in Fall 2026, and SP16 IND was accepted with Phase 1b enrollment starting mid-2026, fully funded by the National Cancer Institute.


Analysis · DWTX · Life Sciences

Dogwood Therapeutics reported a significantly reduced net loss for Q1 2026 and extended its cash runway into Q4 2026. Crucially, the company announced a worldwide development and commercialization partnership for its legacy antiviral assets with a potential value of up to $100 million. This partnership represents a substantial potential monetization event for a company with a $62 million market cap, directly addressing prior concerns about its ability to continue as a going concern.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 51% of the 200 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.88%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DWTX was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.1M. The 52-week trading range was $1.28 to $9.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DWTX - Latest Insights

DWTX
Nov 06, 2026, 9:18 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.31 info
Change: +$0.210 (+19%) info
Market Cap: $48.932M info
DWTX
Nov 05, 2026, 8:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $1.31 info
Change: +$0.210 (+19%) info
Market Cap: $48.932M info
DWTX
Oct 19, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.31 info
Change: -$0.050 (-4%) info
Market Cap: $48.932M info
DWTX
Oct 19, 2026, 8:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $1.31 info
Change: +$0.060 (+5%) info
Market Cap: $48.932M info
DWTX
Sep 14, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.31 info
Change: -$0.730 (-36%) info
Market Cap: $48.932M info